DelveInsight's report titled "Focal Segmental Glomerulosclerosis Pipeline Insight 2023" offers extensive information on more than 15+ companies and over 18+ pipeline drugs in the field of Focal Segmental Glomerulosclerosis research. The Focal Segmental Glomerulosclerosis pipeline report encompasses detailed profiles of the pipeline drugs for Focal Segmental Glomerulosclerosis, including information on Focal Segmental Glomerulosclerosis clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.
For the Focal Segmental Glomerulosclerosis emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Focal Segmental Glomerulosclerosis pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Focal Segmental Glomerulosclerosis clinical trial studies conducted for Focal Segmental Glomerulosclerosis, any NDA approvals obtained for Focal Segmental Glomerulosclerosis, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Focal Segmental Glomerulosclerosis Pipeline treatment landscape of the report, click here @ Focal Segmental Glomerulosclerosis Pipeline Outlook
Key Takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report
- DelveInsight’s Focal Segmental Glomerulosclerosis Pipeline analysis depicts a robust space with 15+ active players working to develop 18+ pipeline treatment therapies.
- The leading Focal Segmental Glomerulosclerosis Companies are working in the market include Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others.
- Promising Focal Segmental Glomerulosclerosis Pipeline Therapies in the various stages of development include Propagermanium, Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), CXA-10, RE-021 (Sparsentan), Fresolimumab, GC1008, VX-147, VB119, and others
- DMX-200 is a chemokine receptor (CCR2) blocker and is administered to patients taking an angiotensin II type I (AT1) receptor blocker (ARB), which is the standard of care treatment for focal segmental glomerulosclerosis. DMX-200 has been granted patents in various territories until 2032 and has also been granted Orphan Drug Designation by the FDA and EMA.
- Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate selectively targeting the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease reduces proteinuria, protects podocytes, and prevents glomerulosclerosis and mesangial cell proliferation. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted sparsentan orphan drug designation for FSGS. Currently, Sparsentan is in Phase III development for the treatment of focal segmental glomerulosclerosis (FSGS).
- Dazodalibep is a CD40 ligand antagonist that blocks T cell interaction with CD40-expressing B cells, disrupting the overactivation of the CD40 ligand co-stimulatory pathway. Several autoimmune diseases are associated with the overactivation of this pathway. Horizon is also investigating dazodalibep in Sjögren’s Syndrome, Rheumatoid Arthritis and Kidney Transplant Rejection. Currently, Dazodalibep is in Phase II development for the treatment of focal segmental glomerulosclerosis (FSGS).
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and end-stage kidney disease (ESKD). The pathogenesis of focal segmental glomerular sclerosis involves a complex interplay of several cell types, including podocytes, endothelial cells, and the basement membrane.
For further information, refer to the detailed Focal Segmental Glomerulosclerosis Unmet Needs, Focal Segmental Glomerulosclerosis Market Drivers, and Market Barriers, click here for Focal Segmental Glomerulosclerosis Ongoing Clinical Trial Analysis
Focal Segmental Glomerulosclerosis Emerging Drugs Profile
- DMX-200: Dimerix Bioscience
- Sparsentan: Travere Therapeutics
- Dazodalibep: Horizon Therapeutics
Focal Segmental Glomerulosclerosis Therapeutics Assessment
There are approx. 15+ Focal Segmental Glomerulosclerosis companies which are developing the therapies for Focal Segmental Glomerulosclerosis. The Focal Segmental Glomerulosclerosis companies which have their Focal Segmental Glomerulosclerosis drug candidates in the most advanced stage, i.e. phase III include, Dimerix Bioscience.
Request a sample and discover the recent advances in Focal Segmental Glomerulosclerosis Ongoing Clinical Trial Analysis and Medications, click here @ Focal Segmental Glomerulosclerosis Treatment Landscape
Focal Segmental Glomerulosclerosis Segmentation
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Focal Segmental Glomerulosclerosis Therapeutics Market include-
Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others.
Dive deep into rich insights for drugs for Focal Segmental Glomerulosclerosis Pipeline, click here @ Focal Segmental Glomerulosclerosis Unmet Needs and Analyst Views
Scope of the Focal Segmental Glomerulosclerosis Pipeline Report
- Coverage- Global
- Focal Segmental Glomerulosclerosis Companies- Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others.
- Focal Segmental Glomerulosclerosis Therapies- Propagermanium, Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), CXA-10, RE-021 (Sparsentan), Fresolimumab, GC1008, VX-147, VB119, and others.
- Focal Segmental Glomerulosclerosis Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Focal Segmental Glomerulosclerosis Mergers and acquisitions, Focal Segmental Glomerulosclerosis Licensing Activities @ Focal Segmental Glomerulosclerosis Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Focal Segmental Glomerulosclerosis Executive Summary
- Focal Segmental Glomerulosclerosis: Overview
- Focal Segmental Glomerulosclerosis Pipeline Therapeutics
- Focal Segmental Glomerulosclerosis Therapeutic Assessment
- Focal Segmental Glomerulosclerosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- DMX-200: Dimerix Bioscience
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Dazodalibep: Horizon Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Focal Segmental Glomerulosclerosis- Unmet Needs
- Focal Segmental Glomerulosclerosis- Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment
